Travere therapeutics announces late-breaker presentations of the interim analysis from the phase 3 protect study of filspari™ (sparsentan) in iga nephropathy at the isn world congress of nephrology and nkf spring clinical meetings 2023

San diego, march 23, 2023 (globe newswire) -- travere therapeutics, inc. (nasdaq: tvtx) today announced that the interim analysis of efficacy and safety data from the ongoing phase 3 protect study evaluating filspari™ (sparsentan) in iga nephropathy (igan) will be presented in late-breaking trial sessions at both the isn world congress of nephrology in bangkok, thailand, march 30-april 2 (isn-wcn), and nkf spring clinical meetings in austin, tx, april 11-15, 2023 (nkf).
TVTX Ratings Summary
TVTX Quant Ranking